In this study we found that serum visfatin was significantly elevated in early RA patients compared to healthy controls and significantly decreased after three months of treatment. Circulating visfatin and a change in visfatin level correlated with disease activity and improved disease activity over time.
Furthermore, a decrease in visfatin after three months predicted disease activity improvement after 12 months